Haemonetics (HAE) Could Be 10% Undervalued On Its Margin Expansion Story
Haemonetics (HAE) has drawn attention after recent share price moves, including a gain of about 7% over the past month and roughly 26% over the past 3 months. These changes are prompting closer examination of its fundamentals.
See our latest analysis for Haemonetics.
At a share price of $77.86, Haemonetics shows recent momentum with a 30 day share price return of 7.05% and a 90 day share price return of 26.36%. This is set against a more modest 1 year total shareholder return of 7.32% and a 3 year total shareholder return that declined 15.77%, suggesting short term enthusiasm has picked up after a weaker multi year experience.
If Haemonetics has caught your attention and you want to see what else is moving, this is a good moment to broaden your search and uncover 39 healthcare AI stocks
Haemonetics looks like a solid medical technology business, and the recent share price jump has put it back on many watchlists. The next step is to see whether that quality is already fully reflected in today’s valuation.
Most Popular Narrative: 10.4% Undervalued
Against Haemonetics' last close at $77.86, the most followed narrative points to a fair value of $86.90, framing the current setup as a discount that hinges on execution and capital allocation.
Enterprise-wide portfolio transformation, highlighted by the divestiture of low-margin businesses, disciplined capital deployment, and ongoing investment in automation and digital solutions, is driving substantial gross and operating margin expansion (guidance of 26–27% for FY26) and is likely to support further improvements in net margins and free cash flow conversion.
Want to understand why this fair value sits meaningfully above today’s price? The core of the narrative hinges on a specific earnings glide path, tighter margins, and a valuation multiple that needs to hold together over several years.
Result: Fair Value of $86.90 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Haemonetics narrative could be knocked off course if competition pressures pricing in core products, or if U.S. centric exposure magnifies any regulatory or reimbursement setbacks.
Find out about the key risks to this Haemonetics narrative.
Another View: Haemonetics Through the P/E Lens
While the narrative and fair value work suggest Haemonetics could be trading at a discount, the current P/E of 36.4x tells a stricter story. It sits above the US Medical Equipment industry at 27.5x and above its own fair ratio of 31.5x, which points to valuation risk if sentiment cools.
For a closer look at how this pricing gap lines up with earnings quality and future expectations, it is worth examining the detailed valuation breakdown behind that fair ratio, including how peers are trading and what would need to change for sentiment to shift toward it: See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If this mix of optimism and caution around Haemonetics feels familiar, you may want to review the data for yourself and weigh both sides, starting with 2 key rewards and 3 important warning signs.
Looking for more investment ideas beyond Haemonetics?
If Haemonetics has sharpened your focus, do not stop here. Use the Simply Wall Street Screener now to spot other clear opportunities before the crowd does.
- Target dependable cash generators by reviewing companies with resilient payouts among 8 dividend fortresses.
- Hunt for value by scanning quality stocks that appear mispriced in the market using 47 high quality undervalued stocks.
- Prioritise resilience by focusing on companies with stronger balance sheets and fundamentals through the solid balance sheet and fundamentals stocks screener (47 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com